The company said its PCV14 is comparable, in terms of serotype coverage for infants, to the two pneumococcal conjugate vaccines – Pfizer’s Prevnar13 and Merck’s VAXNEUVANCE -- that are currently approved globally.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/dxb8F0D
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» SEC recommends Bio E’s 14-valent pneumococcal conjugate vaccine PCV14 for infants
https://ift.tt/JUV2tG3
No comments:
Post a Comment